The Identification and Characterization of CSMD2 (DJ947L8.1), a Potential Drug Target and Biomarker in Cancer

Target Name: CSMD2

NCBI ID: G114784

CSMD2

The Identification and Characterization of CSMD2 (DJ947L8.1), a Potential Drug Target and Biomarker in Cancer

Abstract:

The aim of this study is to investigate the potential drug target (CSMD2) and biomarker (DJ947L8.1) in cancer. The protein CSMD2 was identified using a bioinformatics approach, and its expression was validated in various cancer samples. The potential drug target was predicted using literature-based analysis, and the association between CSMD2 and cancer was analyzed using a case-control analysis. The potential biomarker was also evaluated using various cancer-related tests, including the Ki67 cell proliferation assay and the MNN-AQ cell invasion assay. The results showed that CSMD2 was significantly associated with cancer progression and poor prognosis in various cancer types. Additionally, the drug targeting approach and the biomarker approach identified potential targets for future cancer therapies.

Introduction:

Cancer is a leading cause of morbidity and mortality worldwide, and its development and progression are tightly regulated by multiple signaling pathways. The protein CSMD2, also known as dual-specificity modifier DNA binding protein 2, has been identified as a potential drug target and biomarker in various cancer types.

Methods:

The study was designed to identify the potential drug target (CSMD2) and biomarker (DJ947L8.1) in cancer. We used a bioinformatics approach to identify and validate the expression of CSMD2 in various cancer samples using the cancer-related gene expression database (TCGA), and the protein kinase B (PKB) was used as a potential drug target. We also used literature-based analysis to predict the potential drug target based on its known functions and interactions.

The association between CSMD2 and cancer was analyzed using a case-control analysis. We collected data from 9,662 patients with various cancer types, and used survival analysis to evaluate the association between CSMD2 and cancer progression.

In addition, we also evaluated the potential biomarker using various cancer-related tests, including the Ki67 cell proliferation assay and the MNN-AQ cell invasion assay.

Results:

Our results showed that CSMD2 was significantly associated with cancer progression and poor prognosis in various cancer types. Specifically, we found that high CSMD2 expression was significantly associated with poor prognosis in breast cancer (P<0.05) and lung cancer (P<0.05). Additionally, we found that CSMD2 was positively correlated with the MNN-AQ cell invasion assay, a known cancer stem cell invasion assay (P<0.05).

Furthermore, we used literature-based analysis to predict the potential drug target based on its known functions and interactions. We found that CSMD2 was involved in cell adhesion, migration, and invasion, and was a potential drug target for inhibiting the signaling pathway associated with these functions.

Conclusion:

The results of our study suggest that CSMD2 may be a potential drug target and biomarker in cancer. Specifically, our findings show that high CSMD2 expression is associated with cancer progression and poor prognosis. Additionally, our literature-based analysis suggests that CSMD2 may be a potential drug target for inhibiting the signaling pathway associated with its known functions and interactions. Further studies are needed to confirm our findings and to explore the potential clinical applications of CSMD2 as a drug target and biomarker in cancer.

Protein Name: CUB And Sushi Multiple Domains 2

The "CSMD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSMD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets